This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steiner, S. Articles by Kopp, C. W. Search for Related Content PubMed PubMed Citation Articles by Steiner, S. Articles by Kopp, C. W. Related Collections Coagulation Other Treatment Growth factors/cytokines Related Article

(Circulation. 2005;111:1841-1846.)
© 2005 American Heart Association, Inc.

Vascular Medicine

Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo

Sabine Steiner, MD; Walter S. Speidl, MD; Johannes Pleiner, MD; Daniela Seidinger, MTA; Gerlinde Zorn, MTA; Christoph Kaun, CTA; Johann Wojta, PhD; Kurt Huber, MD; Erich Minar, MD; Michael Wolzt, MD; Christoph W. Kopp, MD

From the Second Department of Medicine, Divisions of Angiology (S.S., D.S., E.M., C.W.K.) and Cardiology (W.S.S, G.Z., C.K., J.W.), and the Department of Clinical Pharmacology (J.P., M.W.), Medical University of Vienna, and the Department of Medicine, Cardiology, and Emergency Medicine (K.H.), Wilhelminenhospital, Vienna, Austria.

Correspondence to Christoph W. Kopp, MD, Second Department of Medicine, Division of Angiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail christoph.kopp{at}univie.ac.at

Received August 14, 2004; revision received November 22, 2004; accepted November 24, 2004.

Background— Beyond lipid lowering, various antiinflammatory properties have been ascribed to statins. Moreover, in vitro studies have suggested the presence of anticoagulant effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, as lipopolysaccharide (LPS)-induced monocyte tissue factor (TF) was suppressed. In this study, we examined the role of statins in experimental endotoxemia on inflammatory and procoagulant responses in vivo.

Methods and Results— In this double-blind, placebo-controlled, parallel-group study, 20 healthy, male subjects were randomized to receive either simvastatin (80 mg/d) or placebo for 4 days before intravenous administration of LPS (20 IU/kg IV). Plasma high-sensitive C-reactive protein (hsCRP), monocyte chemoattractant protein (MCP-1), sCD40L, sCD40, and prothrombin fragment F1+2 (F1.2) were determined by ELISAs at baseline and at 4 and 8 hours after LPS administration. Monocyte TF expression and monocyte-platelet aggregates were measured by whole-blood flow cytometry over the same time course. The increases in hsCRP and MCP-1, both known inducers of TF, were significantly suppressed by statin treatment after LPS challenge. Statin premedication blunted the increase of monocyte TF expression in response to LPS. In parallel, endotoxin-induced formation of F1.2 was significantly reduced by simvastatin after 4 and 8 hours. LPS infusion affected neither the formation and activation of monocyte-platelet aggregates nor plasma levels of sCD40 and sCD40L.

Conclusions— Simvastatin suppresses the inflammatory response to endotoxin and blunts monocyte TF expression but does not affect platelet activation.

Key Words: statins • inflammation • thrombosis

Related Article:

Should Treatment of Sepsis Include Statins?

Ascan Warnholtz, Sabine Genth-Zotz, and Thomas Münzel
Circulation 2005 111: 1735-1737. [Full Text]

This article has been cited by other articles:

				F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]

				R. Mahajan, R. Gupta, and A. Sharma Beneficial Effects of Statin Therapy on Infection Related Mortality in Patients with Atherosclerotic and Cardiovascular Disease Anesth. Analg., January 1, 2008; 106(1): 352 - 352. [Full Text] [PDF]

				M.W. Merx and C. Weber Sepsis and the Heart Circulation, August 14, 2007; 116(7): 793 - 802. [Abstract] [Full Text] [PDF]

				G. M. Howard-Alpe, J. W. Sear, and P. Foex Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers Br. J. Anaesth., December 1, 2006; 97(6): 758 - 769. [Abstract] [Full Text] [PDF]

				N. N. Boushra and M. Muntazar Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives: [Le role des statines dans la reduction du risque cardiaque perioperatoire : perspectives physiologiques et cliniques]. Can J Anesth, November 1, 2006; 53(11): 1126 - 1147. [Abstract] [Full Text] [PDF]

				A. Yilmaz, C. Reiss, A. Weng, I. Cicha, C. Stumpf, A. Steinkasserer, W. G. Daniel, and C. D. Garlichs Differential effects of statins on relevant functions of human monocyte-derived dendritic cells J. Leukoc. Biol., March 1, 2006; 79(3): 529 - 538. [Abstract] [Full Text] [PDF]

				J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]

				A. Warnholtz, S. Genth-Zotz, and T. Munzel Should Treatment of Sepsis Include Statins? Circulation, April 12, 2005; 111(14): 1735 - 1737. [Full Text] [PDF]